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Complement factor B (FB) mutant variants are associated with excessive complement
activation in kidney diseases such as atypical hemolytic uremic syndrome (aHUS), C3
glomerulopathy and membranoproliferative glomerulonephritis (MPGN). Patients with
aHUS are currently treated with eculizumab while there is no specific treatment for
other complement-mediated renal diseases. In this study the phenotype of three FB
missense variants, detected in patients with aHUS (D371G and E601K) and MPGN
(I242L), was investigated. Patient sera with the D371G and I242L mutations induced
hemolysis of sheep erythrocytes. Mutagenesis was performed to study the effect of factor
D (FD) inhibition on C3 convertase-induced FB cleavage, complement-mediated
hemolysis, and the release of soluble C5b-9 from glomerular endothelial cells. The FD
inhibitor danicopan abrogated C3 convertase-associated FB cleavage to the Bb fragment
in patient serum, and of the FB constructs, D371G, E601K, I242L, the gain-of-function
mutation D279G, and the wild-type construct, in FB-depleted serum. Furthermore, the
FD-inhibitor blocked hemolysis induced by the D371G and D279G gain-of-function
mutants. In FB-depleted serum the D371G and D279G mutants induced release of
C5b-9 from glomerular endothelial cells that was reduced by the FD-inhibitor. These
results suggest that FD inhibition can effectively block complement overactivation induced
by FB gain-of-function mutations.
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The innate immune system is a first line of defense against
pathogens and contributes to removal of apoptotic host cells.
One of the mainstays of protection is the complement system
responding to non-self molecules and eliminating them or
neutralizing their effects by opsonization or lysis as well as
induction of leukocyte chemoattraction, inflammation and
phagocytosis (1). The main enzymatic activity of the
alternative complement pathway is mediated by the C3
convertase. For C3 convertase formation to occur C3b binds to
factor B (FB) which is cleaved by factor D (FD) to the Ba and Bb
fragments, the latter possessing catalytic activity. Bb remains
bound to C3b and forms the C3bBb convertase that
exponentially cleaves more C3 into C3a and C3b. Binding of
additional C3b molecules generates the C5 convertase. The
complement system is kept in balance by multiple cellular and
soluble regulators (1).
FB is essential for defense against encapsulated bacteria, and
thus individuals with FB deficiency are prone to infection with
Neisseria meningitidis and Streptococcus pneumoniae (2).
Conversely, an overactive FB can lead to excessive complement
activation via the alternative pathway resulting in kidney diseases
such as atypical hemolytic uremic syndrome (aHUS) or C3
glomerulopathy. In both of these rare conditions, patients may
exhibit complement activation but there are distinct differences
in clinical presentation and renal pathology. While aHUS is
characterized by hemolytic anemia, thrombocytopenia and renal
failure with lesions indicative of thrombotic microangiopathy
(3), C3 glomerulopathy is a form of chronic glomerulonephritis
presenting with hematuria and proteinuria leading to renal
failure (4). These conditions can arise due to mutant variants
in complement factors, including CFB mutations, or auto-
antibodies against factor H (5). Autoantibodies against FB have
been described in C3 glomerulopathy (6).
In aHUS the complement system is overactive due to loss-of-
function mutations in complement regulators or gain-of-
function mutations in C3 or CFB (7). Gain-of-function
variants in CFB are rare and have in certain cases been
associated with low C3 levels in patient sera (8–11) indicating
complement activation in vivo. Mutations have been shown to
increase FB binding affinity to C3b thereby stabilizing the C3bBb
convertase (12) and enhancing resistance to factor H mediated
decay acceleration (9, 13). This was particularly demonstrated
for mutations located in close proximity to the C3b binding
region, i.e. the Mg2+-binding site in the von Willebrand factor
type A domain of FB (14). Of note, not all CFB mutations have
been shown to induce complement activation and not all
individuals carrying CFB mutations associated with aHUS
develop disease (11, 12, 14), even if circulating C3 levels are
low. In addition to aHUS, CFB mutations and rare variants have
also been demonstrated in C3 glomerulopathy and immune
complex-associated membranoproliferative glomerulonephritis
(MPGN) (15–17).
Binding of C3b to FB elicits a conformational change
exposing the scissile bond at position Arg234-Lys235 enabling
cleavage by FD (18). Small molecule FD inhibitors have beenFrontiers in Immunology | www.frontiersin.org 2developed as potential treatments for complement-mediated
diseases (19) and efficiently inhibited activation of the alternative
pathway in vitro as well as in animal models (19, 20). FD inhibitors
present the advantage of blocking complement activation at the
level of the C3 convertase, while leaving the classical and lectin
pathways intact. A phase 2 trial has been completed and a phase 3
trial with an oral FD inhibitor as an add-on therapy to C5
inhibition is ongoing in patients with paroxysmal nocturnal
hemoglobinuria (PNH) (21, 22).
The aim of this study was to investigate if FD inhibition
impacted complement overactivation induced by CFB
mutations. To this end we investigated four CFB mutations
associated with aHUS or MPGN, two of which mediate a gain-
of-function phenotype. We studied the effect of FD inhibition in
the presence of the FB mutations on C3 convertase-induced FB
cleavage, complement-mediated hemolysis, and release of
soluble C5b-9 from glomerular endothelial cells.MATERIALS AND METHODS
Subjects
Patients from Iceland, Sweden and Norway with complement-
mediated renal diseases are referred to the laboratory at the Dept
of Pediatrics in Lund for genetic diagnostics. Three patients were
found to have CFB mutations. The patients and their laboratory
data are presented in Table 1. Samples were obtained from
apparently healthy adult controls (n=12, 6 female) who were not
using any medications. The study of patients and healthy
controls was performed with the approval of the Ethics Review
Board at Lund University. Approval included genetic analysis of
Nordic patients and phenotypic studies of complement
mutations. The study was also approved by the National
Bioethics Committee of Iceland and the Data Protection
Officer at Oslo University Hospital, Oslo Norway. Informed
written consent was obtained from the patients or the parents
of Patient 3 and the healthy controls.
Blood Samples
Whole blood in EDTA tubes was used for DNA purification.
Serum samples were taken during chronic disease in Patients 1-3
and from healthy controls, centrifuged after one hour at room
temperature and stored at -80°C until assayed.
Genetic Analysis and Mutation Screening
Next generation sequencing was performed focusing on a panel
of genes encoding the following 17 proteins: complement C3,
CFB, factor H (CFH), factor H-related proteins-1, -2, -3, -4, -5,
C5, factor I, properdin, CD46 (membrane co-factor protein), a
disintegrin and metalloproteinase with a thrombospondin type 1
motif 13 (ADAMTS13), diacylglycerol kinase epsilon (DGKE),
plasminogen, thrombomodulin and clusterin.
Whole-exome sequencing was performed at the Center for
Molecular Diagnostics, Skåne University Hospital and Clinical
Genomics Lund, SciLifeLab. In brief, genomic DNA was subject
to tagmentation-based library preparation and hybrid captureJune 2021 | Volume 12 | Article 690821
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the manufacturer’s instructions. Captured exome libraries were
sequenced 2 x 150 bp on a Next Seq 500 (Illumina, San Diego,
CA). Alignment and variant calling were performed according to
GATK “Best Practices for Germline SNP & Indel Discovery in
Whole Genome and Exome Sequence”. Sequence data was
mapped to the hg19 genome build using BWA 0.7.15 (23) and
variants were called using HaplotypeCaller from GATK 3.7 and
processed according to the best practice recommendations (24,
25). Variants were annotated using Ensembl Variant Effect
Predictor release 87. Reported variants with frequencies <2%
according to Genome Aggregation Database (gnomAD) were
included in the genetic evaluation.
Measurement of Anti-Factor B Antibodies
Factor B antibodies were measured in serum as previously
described (6). A Nunc Maxisorp 96 well plate (Thermo
Scientific, Roskilde, Denmark) was coated with FB
(Complement Technologies, Tylor, Texas). Bound IgG was
detected with anti-human IgG:horse radish peroxidase (DAKO,
Glostrup, Denmark).
Mutagenesis
A plasmid containing wild-type CFB, or variants D279G, or I242L
cDNA in the expression vector, pcDNA 3.1/V5-His TOPO
(Invitrogen, Thermo Fisher, Carlsbad, CA) was previously
described (12, 26). For the FB variants D371G and E601K
mutagenesis was performed using the QuikChange II XL Site-
DirectedMutagenesis Kit (Agilent Technologies, Santa Clara, CA).
Primers are available upon request. Mutant sequences were
verified by enzymatic digestion with restriction enzymes. XL-10
Gold ultracompetent cells (Agilent) were used for transformation.
Constructs were Sanger sequenced to confirm that no additional
mutations had been introduced.Frontiers in Immunology | www.frontiersin.org 3Transient Transfection
Transfection was performed as previously described (27).
Briefly, human embryonic kidney 293 cells (HEK) cells
(ATCC, Teddington, Middlesex, UK) were seeded and
grown in DMEM/high glucose Hyclone medium (GE
Healthcare Life Sciences, South Logan, UT), supplemented
with 100 U/mL penicillin, 100 mg/mL streptomycin and 10%
fetal bovine serum to approximately 95% confluence before
transfection. Plasmid DNA (2 mg) was added to each well and
transfection performed with Lipofectamine (Invitrogen, Life
Technologies, Waltham, MA) according to the manufacturer’s
instructions. Twenty-four h after transfection, the medium
was changed to Optimem (Thermo Fisher Scientific) and cells
were cultured for an additional 72 h. The media were collected
and supplemented with protease inhibitors cOmplete Mini
without EDTA (Roche Diagnostic, Mannheim, Germany) and
centrifuged to remove cell debris.
Determination of Factor B Size
by Immunoblotting
FB size in sera and cell media was determined by
immunoblotting. Sera was diluted 1:2000, samples were
reduced with mercapto-ethanol and incubated at 100°C for 5
minutes. Proteins were separated by SDS electrophoresis and
transferred to a PVDF membrane. Plasma purified FB (1 mg/
mL, Complement Technology, Tyler, Texas) was used as the
control. Membranes were blocked overnight. Polyclonal goat
anti-human FB antibody (1:1000, Complement Technology)
was used as the primary antibody followed by rabbit anti-
goat horse-radish-peroxidase (1:1000, DAKO, Glostrup,
Denmark). Detection was performed by chemiluminescence
(Pierce lECL2, Western Blotting Substrate, Rockford,
IL) and detected using ChemiDoc™ Touch, Bio-Rad
(Hercules, CA).TABLE 1 | Clinical characteristics of patients included in this study.
















Factor H DGKE ADAMTS13
1 M 1 aHUS Uremia TMA CKD stage 5 0.4 100 D371G – – –




2 F 54 aHUS Uremia NA CKD stage 3 0.9 66 E601K – Q560R –
Eculizumab
Recurrence 0
3c F 6 MPGN Nephrotic
syndrome
MPGN CKD stage 5 0.75 79 I242L V62I
N1050Y
– P457L
C3, C1q, C5b-9 and IgM
deposition
EculizumabJune 2021 | Volume 12 | AaAll genetic variants shown are heterozygous. bTwo kidney transplants were performed before the eculizumab era, the first functioned for 15 years and the second for 7 years. Three years
after the second transplant, treatment with eculizumab was initiated due to HUS recurrence and was continued until the patient returned to dialysis. Eculizumab therapy was restarted at
the time of the third kidney transplant without evidence of recurrence. cThis patient underwent two biopsies within 2 months, C3 deposits in capillary walls and mesangium increased in the
second biopsy. The patient did not have circulating C3 nephritic factor. DGKE, diacylglycerol kinase epsilon; aHUS, atypical hemolytic uremic syndrome; TMA, thrombotic
microangiopathy; CKD, chronic kidney disease; MPGN, membranoproliferative glomerulonephritis; NA, not available/not performed. Normal reference values for C3: 0.5-0.95 g/L
(Patient 1) 0.77-1.38 g/L (Patients 2 and 3), reference values vary between different clinical laboratories; Factor B: 75-125% (Patient 1), 59-154% (Patients 2 and 3). Patients 1 and 2 did not
have antibodies against factor H.rticle 690821
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FB concentration of constructs was quantified by ELISA using
mouse anti-human factor Ba (Quidel, San Diego, CA) for capture
and goat anti-human FB polyclonal antibody (Complement
Technology) for detection, followed by rabbit anti-goat horse-
radish-peroxidase (HRP, 1:1000, DAKO, Glostrup, Denmark),
alternatively an ELISA kit for detection of human FB (Abcam,
Cambridge UK) showing comparable FB levels. Plasma purified
FB was used as the standard. Absorbance was measured at 450
nm using Glomax Discover (Promega, Madison, WI).
Complement Activation on Primary
Glomerular Endothelial Cells
Primary glomerular endothelial cells (Cell Systems, Kirkland, WA)
were plated on cell culture slides (Thermo Fisher Scientific) in
endothelial growth medium (EGM-2, Lonza, Walkersville, MD),
approximately 75000 cells per well and cultured to monolayer
confluence. Cells were activated with adenosine diphosphate
(ADP, 1 mM, Sigma-Aldrich) in serum-free EGM-2 for 10 min
and washed with PBS with Mg/Ca (GE Life Sciences). Serum
samples were diluted 1:4 in serum-free EGM-2 and magnesium-
ethylene glycol-bis(2-aminoethylether)-N N N´N`-tetraacetic acid
(Mg-EGTA, Complement Technology) 0.1M 1:10, incubated with
the cells for 2 h at 37°C. Cells were washed, fixed in
paraformaldehyde 4% for 30 min, washed thrice and blocked in
1% BSA for 30 min. C3c deposition on the cells was detected using
rabbit anti-human C3c antibody:FITC (DAKO, Glostrup,
Denmark) diluted 1:50 in 1% BSA for 1 h. Cells were stained
with 4´,6-diamidino-2-phenylindole (DAPI, Thermo Fisher,
Eugene, OR). Fluorescence was detected using a Ti-E inverted
fluorescence microscope equipped with a Nikon structured
illumination microscopy module (Nikon Instruments, Tokyo,
Japan). Image stacks at 10 x magnification were converted to
maximal intensity images. Stained cells were outlined with a
threshold above the background to select the area occupied by
cells (DAPI-positive). Quantification was performed using ImageJ
Fiji Software (Version 1.53h, NIH, Bethesda, MD).
In certain experiments the cells were incubated with FB constructs
(50 mg/mL) in FB-depleted serum diluted 1:4 in serum-free EGM-2.
The FB constructs were preincubated with and without the FD
inhibitor danicopan ACH- 4471 (MedChemtronica AB, Monmouth
Junction, NJ) 10 mM for 15 min before a 2-hour incubation with the
cells. Cell supernatants were collected and kept at -20°C until assayed
using the sC5b-9 ELISA described below.
Hemolytic Assays Using Human Sera and
Factor B Constructs
Complement activation in serum was assayed by incubation of
the serum with sheep erythrocytes (5x108/mL, Håtunalab, Bro,
Sweden). Serum (20%) was added to gelatin veronal buffer
(GVB) with Mg-EGTA 0.1M 1:10 to which normal human
serum (20%) was added, as a source of normal C3, for 10 min
at 30°C (28). Ethylenediaminetetraacetic acid (EDTA) 10 mM
was added, and samples were centrifuged. Rat serum in EDTA
(1:5, Complement Technology) was added, as a source of the
terminal complement pathway, for 1 h at 37°C and samples wereFrontiers in Immunology | www.frontiersin.org 4centrifuged. Absorbance was measured at 405 nm using Glomax
Discover (Promega, Madison, WI).
Rabbit erythrocytes (5x108/mL, Håtunalab) were used in GVB-
Mg-EGTA buffer, as above, and incubated with FB constructs 5 mg/
mL in FB-depleted serum (Complement Technology). Samples
were incubated for 1 h on a shaker at 37°C, after which
complement activation was terminated by addition of EDTA
(Complement Technology). In certain experiments the FD
inhibitor was incubated with erythrocytes in buffer to which FB-
depleted serum was added before addition of the constructs.
Absorbance was measured at 405 nm using Glomax Discover.
Binding of Factor B Constructs to C3
Measured by Surface Plasmon Resonance
Purified C3b (33 mg/mL in 10 mM sodium acetate (GE Healthcare
Bio-Sciences), pH 5.0, Complement Technology) was amine-
coupled to a CM5 sensor chip (GE Healthcare) corresponding
to 5517.3 response units. The surface of the sensor chip was
activated with a mixture of N-hydroxysuccinimide and 1-ethyl-3-
(3-dimethylaminoipropyl) -carbomide. After covalent binding of
C3b to the dextran matrix the surface was blocked with
ethanolamine. Running buffer (10 mM Hepes (pH 7.4), 50 mM
NaCl, 10 mMMgCl2) was injected over the flow cells at a flow rate
of 10 mL/min and 25°C. The C3 convertase was generated as
previously described (29) by serial injections of FB 0.28 µg (60
nM) together with FD 0.02 µg in 50 µl running buffer followed by
C3(H2O) 2 µg. After the last step (FB+FD) the surface was
extensively washed with 3 M NaCl in acetate buffer (pH 5.2) and
50mMNaOH to rinse away residual noncovalently bound proteins.
Additional experiments were performed to study the
interaction between C3b and FB. C3b was diluted in 10 mM
sodium acetate (pH 5.5) at a concentration of 20 mg/mL, and
then immobilized as above. The D371G, D279G and wild-type
constructs were injected at a flow rate of 30 mL/min and at 25°C
over the flow cells using a running buffer containing 10 mM
Hepes, 150 mm NaCl, 0.005% surfactant P20, 3.4 mM EDTA
(pH 7.5) and 10 mMMgCl2. The equilibrium constant (KD) was
calculated. The regeneration buffers used were 10 mM glycine-
HCl pH 1.5 and 0.5 M sodium chloride.
Assays were performed using a Biacore X100 instrument (GE
Healthcare). Biacore X100 Evaluation Software version 2.0.1 and
1.0.1 was used for sensogram generation. Baseline values were
adjusted to pre-sample injection levels at t=0 in each cycle in
order to compare binding.
Factor B Cleavage by Factor D
in Solid Phase
Microtiter wells were coated with C3b at 3 mg/mL diluted in
phosphate-buffered-saline (PBS) overnight and blocked with
bovine serum albumin (BSA, Sigma) for 1 h. Serum, 20% in
Mg- PBS, or FB constructs 5 mg/mL in assembly buffer (Mg, FD
100 ng/mL in PBS with BSA 1%), were incubated for 30 min at
37°C and an additional 30 min with slow shaking. Samples were
washed four times with PBS-Tween 20 0.1%. Twenty ml 10 mM
EDTA with sodium dodecyl sulfate (SDS) 1% were added to the
empty wells for 1 h on a microplate shaker 1000 rpm at rt.June 2021 | Volume 12 | Article 690821
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and samples were stored at -20°C. In certain samples the FD
inhibitor at 10 mM (final concentration) was preincubated with
the samples for 15 min before addition to the plate.
Samples were reduced and loaded onto a Tris-TGX gel 10%
(Bio Rad) and after protein separation transferred to PVDF
membranes (Bio Rad) and electroblotted (Transblot Turbo, Bio
Rad). Immunoblot was carried out with goat anti-FB and rabbit
anti-goat:HRP and detected as described above.
Soluble C5b-9 Measurement
Soluble C5b-9 in the supernatant from activated glomerular
endothelial cells was quantified using the MicroVue SC5-b9
Plus kit (Quidel, San Diego, CA) according to the
manufacturer’s protocol. Absorbance was measured at 450 nm
using Glomax Discover.
Statistics
Kruskal-Wallis multiple-comparison test followed by Dunn’s
procedure was used for evaluating differences between more
than two groups. A P value ≤ 0.05 was considered significant.
Statistical analysis was performed using GraphPad prism 8
software (version 8.4.3, GraphPad Software, La Jolla, CA).RESULTS
Factor B Variants
Three FB mutations were identified in Patients 1-3 (Table 1).
The location of the gene products within FB domains is depictedFrontiers in Immunology | www.frontiersin.org 5in Figure 1. FB variants D371G (rs1258425617) (31) and I242L
(rs1299040443) (7, 12, 32) have been reported before in patients
with aHUS. Variant D371G (rs756325732) is located in the von
Willebrand factor (VWF) type A domain of the Bb fragment, but
far from the C3b binding site (Figure 1). The E601K variant has
not been previously reported and is located in the serine protease
domain, not near the catalytic site, at the VWF type A domain
binding interface in the context of the pro-convertase C3bB (but
not in the convertase C3bBb). The Bb fragment undergoes a
conformational change upon release of Ba, leading to assembly of
the metal ion dependent adhesion site (MIDAS). The mutated
residue is far from the MIDAS, which participates in C3b
binding, but may affect its assembly by allosteric effects
(Figure 1). I242L is located in the linker between Ba and Bb
fragments near the R234-K235 scissile bond (33). The D279G
variant was used as a positive control as it was previously shown
to induce a gain-of-function phenotype (34) and is located in
proximity to the MIDAS in the vonWillebrand factor A domain.
The patients had normal serum FB levels (Table 1) and normal
FB size (Supplementary Figure 1) and did not have
autoantibodies to FB (data not shown).
Phenotypic Assays of the FB Mutations
Assays were performed to investigate the factor B phenotype
using patient sera and mutant constructs, as outlined in Table 2.
C3 Deposition on Glomerular Endothelial Cells
Serum from Patients 1-3 and normal sera (n=10) were incubated
with primary glomerular endothelial cells. Patient sera induced
C3 deposition on the cells which was also detected for 3 normalA
B
FIGURE 1 | The molecular structure of factor B and the location of mutations described in this study. (A) Location of the four mutated residues (D371G, E601K,
I242L and D279G), visualized on the structure of the C3 pro-convertase C3bB depicted in grey (PDB ID 2XWJ) (18) using PyMol. The Metal Ion Dependent Adhesion
Site (MIDAS) on C3b is depicted by a star. The colors of the domains correspond to the domains depicted in (B). (B) The linear structure of factor B divided into the
signal peptide/leader, Ba and Bb fragments with a linker sequence in between. The amino acid numbers are given in parentheses. The protein is composed of a
complement control protein (CCP) domain with three CCPs, followed by the linker, the von Willebrand factor type A domain (VWA) and the serine protease (SP)
domain. The location of mutations studied herein is depicted.June 2021 | Volume 12 | Article 690821
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cells could not be assayed because the patients were treated with
the anti-C5 antibody eculizumab (Table 1).
Patient Sera Induced Hemolysis of Sheep
Red Blood Cells
Sera from Patients 1-3 and normal serum from two healthy
controls were incubated with sheep erythrocytes. Sera from
Patients 1 (FB: D371G) and 3 (FB: I242L, CFH: V62I, N1050Y
and ADAMTS13: P457L) induced hemolysis whereas samples
from Patient 2 (FB: E601K, DGKE: Q560R) and the normal
controls (n=2) did not (Figure 3).
Binding of Factor B Constructs to C3b and
Formation of the C3 Convertase Determined
by Surface Plasmon Resonance
In binding assays, we first examined FB binding to C3b. C3b was
immobilized on a Biacore sensor surface. The purified FB
constructs, D279G (positive control, gain-of-function mutation in
aHUS) (13), D371G, I242L or E601K were injected together withFrontiers in Immunology | www.frontiersin.org 6FD. Sensograms were aligned at t = 0 for comparison and showed
that the FB construct D371G bound most, followed by D279G. The
I242L, E601K and wild-type constructs demonstrated similar
binding capacity (see arrow in Figure 4).
The C3 convertase was assembled on the sensor chip by serial
injections of purified FB and FD followed by C3 (Figure 4) and
showed that the factor B variant D279G yielded the highest binding,
indicating C3 convertase formation, followed by D371G, the wild-
type, E601K and I242L (see arrowhead in Figure 4).
Binding experiments showed that the FB mutant constructs
D279G and D371G exhibited stronger binding to C3 than the
wild-type construct (Figure 4B). Using a concentration range of
the D371G and wild-type constructs (Figure 4C) the Ka, Kd and
KD constant were calculated showing that the D371G construct
had a higher affinity for C3 than the wild-type construct.
Effects of Factor D Inhibition
Factor B Cleavage by the C3 Convertase
A functional C3bBb(Mg2+) complex was formed in a microtiter
plate by incubating C3b-coated wells with serum. In the presenceA B
FIGURE 2 | C3 deposition on glomerular endothelial cells in the presence of serum from patients and controls. Sera from Patients 1-3 and controls (n = 10) were
incubated with glomerular endothelial cells for 2 h and C3 detected by immunofluorescence. (A) Serum from Patients 1-3 induced excessive C3 deposition on the
cells. The scale bar represents 100 µm. (B) Quantification of C3 deposition fluorescence showing that even 3/10 sera from apparently healthy adult controls
exhibited C3 deposition. The bar represents the median.TABLE 2 | Complement functional assays performed in this study using patient sera and mutant constructs.














C3 deposition on glomerular endothelial
cells
+ ND + ND + ND ND 3/10b ND
Hemolysis sheep RBCs + ND – ND + ND ND 0/2 ND
Factor B binding to C3b (surface
plasmon resonance)
ND + ND – ND – + ND –
Factor B degradation by factor D Degr Degr Degr Degr Degr Degr Degr Degr Degr
Hemolysis of rabbit RBCs ND + ND – ND – + ND –
Soluble C5b-9 release from glomerular
endothelial cells
ND + ND – ND – + ND –June 2021 | Volume 12aSerum from Patients 1 and 2 was taken during eculizumab treatment. Serum from Patient 3 was taken before the start of eculizumab treatment. b3/10 indicates positive result in 3 of 10
controls. +, complement activation detected; -, complement activation was not detected; ND, Not done; RBCs, red blood cells; Degr, degradation detected.| Article 690821
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convertase was formed and cleavage of FB to the Bb fragment
was detected (Figure 5A). In the presence of the FD inhibitor,
danicopan ACH- 4471, FB cleavage was inhibited in normal
serum, as well as in the serum of Patients 2 and 3, and partially
inhibited in the serum of Patient 1 in which a weak Bb band was
still visible.
Similarly, the C3b-coated plates were incubated with purified
FB constructs together with FD showing that all constructs, wild-
type, D279G, D371G, E601K and I242L, exhibited FB cleavage to
the Bb fragment, albeit weaker for the I242L variant, and that
cleavage was entirely inhibited in the presence of the FD
inhibitor (Figure 5B).
Complement-Mediated Hemolysis of Rabbit
Red Blood Cells
Rabbit red blood cells were incubated with FB constructs in FB-
depleted serum and underwent hemolysis in the presence of FB
variants D279G andD371Gwhereas the wild-type, as well as E601K
and I242L constructs did not induce hemolysis. The FD inhibitor
inhibited D279G- and D371G-induced hemolysis (Figure 6).
Release of Soluble C5b-9 From Primary Glomerular
Endothelial Cells
Soluble C5b-9 was detected in supernatants from primary
glomerular endothelial cells that were incubated with FB
constructs D279G and D371G in FB-depleted serum. The FB
construct D371G induced increased C5b-9 release compared toFrontiers in Immunology | www.frontiersin.org 7the wild-type construct (Figure 7). In the presence of the FD
inhibitor the soluble C5b-9 levels were comparable with those
released in the presence of the wild-type construct (Figure 7).
Factor B mutant constructs E601K and I242L did not induce
C5b-9 release compared to the wild-type.DISCUSSION
Complement activation is a hallmark of aHUS, C3 glomerulopathy
and MPGN. Here we explored three patients with CFB variants.
One of these variants, D371G, was shown to be a gain-of-function
mutation, as indicated by enhanced binding to C3b, formation of
the C3 convertase, increased hemolysis of rabbit erythrocytes and
release of soluble C5b-9 from glomerular endothelial cells.
Additionally, the D279G variant, also found in aHUS (13), was
used a positive control and exhibited similar properties. Both CFB
variants, D371G and D279G, could be effectively controlled by the
FD small molecule-inhibitor danicopan (ACH-4471). The
remaining two variants did not show gain-of-function but also
did not perturb the inhibitory activity of danicopan. This suggests
that FD inhibition should effectively inhibit complement activation
in these patients.
CFB variants have been described in patients with aHUS (7–14,
31, 35, 36), in C3 glomerulopathy (15, 17) and in a few patients with
immune-complex associatedMPGN (16) but not all of them exhibit
gain-of-function (12). Here we show that the mutant variant
D371G, found in Patient 1, and reported previously (31), induces
a clear-cut gain-of-function. These functional consequences can
explain why the serum from Patient 1, without other complement
mutations, induced C3 deposition on glomerular endothelial cells
and hemolysis of sheep erythrocytes. Increased hemolysis in serum
from this patient, treated with eculizumab at the time of sampling, is
explained by the addition of rat serum, as a source of C5b-9, at
which point the effect of eculizumab is eliminated by a washing step.
A novel CFB mutation E601K, in the serine protease domain of
the protein, was found in Patient 2. This variant did not exhibit gain-
of-function in the tests performed. Therefore, the increased
complement deposition on endothelial cells cannot be explained
by this genetic variant. The patient also had a mutation in the
diacylglycerol kinase epsilon (DGKE) gene. DGKE mutations
associated with aHUS do not directly cause complement activation
and usually present during the first year of life (37), however this
patient first presented with aHUS at mid-life. Thus, we assume that
the DGKE variant was not associated with the patient’s disease.
The FB mutant variant I242L was detected in Patient 3, a
child with what initially appeared to be immune complex-
mediated MPGN. However, a second biopsy within 2 months
showed more C3 deposition and suggested that the child might
develop C3 glomerulopathy over time. This mutation was
previously described in patients with aHUS and did not induce
a clear gain-of-function (12). Serum from the patient induced C3
deposition on glomerular endothelial cells and enhanced
hemolysis of sheep erythrocytes. The child also has previously
reported genetic variants in CFH, V62I and N1050Y (38),
suggesting that complement activation on cells may be aFIGURE 3 | Hemolysis of sheep erythrocytes in the presence of patient and
normal serum. Serum from Patients 1 (factor B mutation D371G) and 3
(I242L) induced hemolysis of sheep erythrocytes whereas serum from Patient
2 and from the two normal controls did not. The results of three separate
experiments are shown. The bar depicts the median.June 2021 | Volume 12 | Article 690821
Aradottir et al. FD-Inhibitor Blocks aHUS/MPGN FB Mutantscombined effect of CFB and CFH variants, although functional
data regarding the CFH variant N1050Y are lacking.
One limitation of this study was that only three patients were
investigated and only one of the three (Patient 1) was found to have
a gain-of-function mutation in factor B (D371G). In Patients 2 and
3 we could not determine a link between the patients’ clinical disease
and the factor B mutations. The absence of functional consequences
of the two CFB mutant variants, E601K and I242L, is in apparent
contradiction with the complement activation observed on
endothelial cells, incubated with patient sera. Ex vivo complement
activation on endothelial cells has been previously reported as
positive in aHUS patients without identified genetic abnormalities
(39). Moreover, it is positive in patients with sickle cell disease (40),
preeclampsia and HELLP syndrome (41) and as shown herein, even
in some apparently healthy controls. In sickle cell disease, the
complement overactivation was mediated, at least in part, by
heme (40, 42). Heme or other pro-inflammatory factors may be
present in the patient sera, activating the endothelial cells, rendering
them susceptible to complement activation. Furthermore, although
serum from Patient 2 induced C3 deposition on endothelial cells the
serum did not induce hemolysis (Table 2) which is in line with theFrontiers in Immunology | www.frontiersin.org 8presence of a pro-inflammatory factor inducing changes on the
surface of endothelial cells which did not fully activate the terminal
complement complex.
FD inhibition has been previously assessed in samples from
patients with the complement-mediated diseases PNH and aHUS.
Low concentrations of FD inhibitors were shown to reduce C3
fragment deposition on PNH erythrocytes as well as complement-
mediated hemolysis (19, 20). Likewise, serum from aHUS patients
induced complement-mediated cell death in PIGA-null PNH-like
cells which was abrogated by the FD-inhibitor (20). The results of
the current study focused on FB mutations utilizing both patient
sera and recombinant mutants, showing that the FD inhibitor
prevented FB cleavage to Bb, hemolysis and the formation of
C5b-9 in the presence of gain-of-function mutations, thereby
blocking excessive complement activation.
Danicopan was found to be effective in preventing complement-
mediated hemolysis in a phase 2 trial in patients with PNH (43). A
phase 3 trial is ongoing in which Danicopan is being investigated as
add-on therapy to C5 inhibitor for patients with PNH with
extravascular hemolysis (22). For patients with aHUS current
consensus recommends treatment with intravenous eculizumab,A
B C
FIGURE 4 | Binding of factor B variants to C3b and formation of the C3 convertase. (A) Purified C3b was coupled to a CM5 sensor chip. Factor B (FB) variants and
factor D (FD) were injected over the surface and binding curves visualized. The FB D371G mutant exhibited the strongest binding to the C3b-coated surface (see
arrow) followed by D279G, I242L, the wild-type (WT) and E601K. This was followed by serial injections of C3 alternating with FB+FD to form the C3 convertase on
the chip. The strongest C3 convertase generation was demonstrated for the D279G mutant (see arrowhead), followed by D371G, the wild-type, I242L and E601K.
Baseline values were adjusted at t = 0 in each cycle for comparison. (B) Binding between C3b and FB alone was assessed using the wild-type construct, D371G
and D279G showing that both mutant constructs, at 50 nM, exhibited stronger binding than the wild-type construct. (C) The coefficient of dissociation was
evaluated using a range of FB concentrations comparing construct D371G to the wild-type.June 2021 | Volume 12 | Article 690821
Aradottir et al. FD-Inhibitor Blocks aHUS/MPGN FB MutantsFIGURE 6 | The effect of factor D inhibition on hemolysis of rabbit erythrocytes. Factor B constructs were incubated in factor B-depleted serum with rabbit
erythrocytes. The mutant variants D279G (positive control) and D371G (corresponding to Patient 1) induced hemolysis. The other mutant constructs (E601K, I242L)
and wild-type (wt) did not induce hemolysis. The factor D inhibitor (FD-inh) inhibited hemolysis induced by factor B mutants D279G and D371G. Eight separate
experiments are shown. ***P < 0.001, ****P < 0.0001.A
B
FIGURE 5 | The effect of factor D inhibition on C3 convertase formation using human serum or factor B mutants. An immunoblot assay was used to detect the Bb
fragment of the alternative pathway C3bBb. (A) C3bBb(Mg2+) complexes were formed by incubating C3b-coated wells with normal serum (NS) or patient serum
(Patients 1-3). The C3 convertase formed in the presence of all sera effectively cleaved factor B to the Bb component and this reaction was inhibited by the factor D
inhibitor. The factor D inhibitor only partially blocked the C3 convertase in the presence of serum from Patient 1(D371G mutation) as a weak Bb band was still visible.
(B) The same assay was performed with the wild-type (WT) and mutant factor B constructs (D371G, E601K, I242L and D279G) showing cleavage to the Bb
fragments and effective inhibition by the factor D inhibitor. FB, factor B; Bb, the Bb fragment of factor B; FD, factor D; FD-inh, factor D inhibitor.Frontiers in Immunology | www.frontiersin.org June 2021 | Volume 12 | Article 6908219
Aradottir et al. FD-Inhibitor Blocks aHUS/MPGN FB Mutantsor ravulizumab (5, 44) thereby blocking C5. FD inhibitors should
also be evaluated in clinical trials either as add-on therapy for C3
glomerulopathy patients, or for aHUS patients in whom C5
inhibition is insufficient, or as an alternative therapy. FD
inhibitors present certain advantages over eculizumab for the
treatment of aHUS. In addition to the extremely high price of
eculizumab (45) and the oral mode of administration of danicopan,
FD blockade will selectively inhibit the alternative pathway and
allow activity of the classic and lectin pathways. Patients treated with
eculizumab are at risk of meningococcal infection due to blockade
of C5b-9 mediated bacterial killing, a risk that is considerably less
with FD inhibitors (46). However, C3 degradation fragments
physiologically promote opsonization and phagocytosis (47)
which are also important for defense against meningococcal
infections. Inhibition of these proximal effects would not occur in
the presence of eculizumab, while they would be impeded in the
presence of an FD inhibitor. In line with this upstream inhibition,
the spike protein of SARS-CoV-2 was shown to activate the
alternative pathway of complement, and a small molecule FD
inhibitor prevented the cellular deposition of C3 fragments and
the generation of C5b-9 (48). Similarly, we could show that
danicopan inhibited formation of the C3 convertase and FB
cleavage as well as release of soluble C5b-9 from cells exposed to
the gain-of-function CFB D371G mutation.Frontiers in Immunology | www.frontiersin.org 10In summary, we describe at the molecular level, the response
of FB mutations to FD inhibition and that FB mutations do not
impact the effective response to FD inhibition. The data suggest
that FD inhibition should be further studied in clinical trials as a
possible treatment for complement-mediated kidney diseases
aHUS, MPGN and C3 glomerulopathy.DATA AVAILABILITY STATEMENT
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